Skip to main content
TipRanks
Go Ultimate75% OFF

Heron Therapeutics (HRTX) Stock Statistics & Valuation Metrics

1,672 Followers

Total Valuation

Heron Therapeutics has a market cap or net worth of $51.94M. The enterprise value is $169.18M.

Market Cap
$51.94M
Enterprise Value
$169.18M

Share Statistics

Heron Therapeutics has 190,273,590 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
190,273,590
Owned by Insiders
5.70%
Owned by Institutions
57.78%

Financial Efficiency

Heron Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -1.59%.

Return on Equity (ROE)
-1.41
Return on Assets (ROA)
-0.08
Return on Invested Capital (ROIC)
-1.59%
Return on Capital Employed (ROCE)
-0.02
Revenue Per Employee
1.21M
Profits Per Employee
-157.77K
Employee Count
128
Asset Turnover
0.61
Inventory Turnover
0.45

Valuation Ratios

The current PE Ratio of Heron Therapeutics is -2.33. Heron Therapeutics’s PEG ratio is 0.03.

PE Ratio
-2.33
PS Ratio
0.34
PB Ratio
10.26
Price to FCF
-3.50
Price to Operating Cash Flow
-3.67
PEG Ratio
0.03

Income Statement

In the last 12 months, Heron Therapeutics had revenue of 154.90M and earned -20.20M in profits. Earnings per share was -0.12.

Revenue
154.90M
Gross Profit
113.56M
Operating Income
-2.54M
Pretax Income
-20.20M
Net Income
-20.20M
EBITDA
-17.88M
Earnings Per Share (EPS)
-0.12

Cash Flow

In the last 12 months, operating cash flow was -13.73M and capital expenditures -631,000, giving a free cash flow of -14.36M billion.

Operating Cash Flow
-13.73M
Free Cash Flow
-14.36M
Free Cash Flow per Share
-0.08

Dividends & Yields

Heron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-28.28%
Earnings Yield
-42.31%

Stock Price Statistics

Beta
1.49
52-Week Price Change
-75.78%
50-Day Moving Average
0.32
200-Day Moving Average
0.62
Relative Strength Index (RSI)
38.63
Average Volume (3m)
4.55M

Important Dates

Heron Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 09, 2026
Next Earnings Date
Mar 04, 2027
Ex-Dividend Date
―

Financial Position

Heron Therapeutics as a current ratio of 2.48, with Debt / Equity ratio of 981.22%

Current Ratio
2.48
Quick Ratio
1.51
Debt to Market Cap
0.65
Net Debt to EBITDA
-6.26
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Heron Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Heron Therapeutics EV to EBITDA ratio is -11.16, with an EV/FCF ratio of -11.90.

EV to Sales
1.15
EV to EBITDA
-11.16
EV to Free Cash Flow
-11.90
EV to Operating Cash Flow
-12.45

Balance Sheet

Heron Therapeutics has $23.45M in cash and marketable securities with $131.73M in debt, giving a net cash position of -$108.28M billion.

Cash & Marketable Securities
$23.45M
Total Debt
$131.73M
Net Cash
-$108.28M
Net Cash Per Share
-$0.57
Tangible Book Value Per Share
$0.03

Margins

Gross margin is 73.81%, with operating margin of -5.69%, and net profit margin of -14.55%.

Gross Margin
73.81%
Operating Margin
-5.69%
Pretax Margin
-14.55%
Net Profit Margin
-14.55%
EBITDA Margin
-10.33%
EBIT Margin
-11.62%

Analyst Forecast

The average price target for Heron Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Neutral

Price Target
―
Price Target Upside
―
Analyst Consensus
Neutral
Analyst Count
1
Revenue Growth Forecast
-4.44%
EPS Growth Forecast
-47.21%

Scores

Smart Score
2
AI Score
43